Journal of the National Comprehensive Cancer Network · 2024 · 110 citations · 25 references
MedicineGynecologyOncologyChemotherapyGynecologic OncologySurgical OncologyCancer StagingFallopian Tube CancerGynecologic Cancer PharmacotherapyOvarian CancerOvarian Cancer PharmacotherapyOvarian Cancer ChemotherapyOvarian Cancer TreatmentOvarian Cytoreductive SurgeryParp InhibitionParp Inhibitor Resistance
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
25
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +15
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +15